[go: up one dir, main page]

CL2022000781A1 - Tratamientos cognitivos medicinales - Google Patents

Tratamientos cognitivos medicinales

Info

Publication number
CL2022000781A1
CL2022000781A1 CL2022000781A CL2022000781A CL2022000781A1 CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1 CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A CL2022000781 A CL 2022000781A CL 2022000781 A1 CL2022000781 A1 CL 2022000781A1
Authority
CL
Chile
Prior art keywords
medicinal
healthy subject
cognitive
treatments
cognitively healthy
Prior art date
Application number
CL2022000781A
Other languages
English (en)
Inventor
Tamara Diane Miller
John William Ketelbey
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903681A external-priority patent/AU2019903681A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of CL2022000781A1 publication Critical patent/CL2022000781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere en general a un método para mejorar la cognición y/o tratar el deterioro cognitivo en un sujeto cognitivamente sano que comprende administrar al sujeto cognitivamente sano una cantidad terapéuticamente efectiva de un compuesto de la Fórmula I, o una sal, solvato o profármaco farmacéuticamente aceptable del mismo, como se describe en la presente.
CL2022000781A 2019-09-30 2022-03-29 Tratamientos cognitivos medicinales CL2022000781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2019903681A AU2019903681A0 (en) 2019-09-30 Medicinal cognitive treatments

Publications (1)

Publication Number Publication Date
CL2022000781A1 true CL2022000781A1 (es) 2022-11-18

Family

ID=75336310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000781A CL2022000781A1 (es) 2019-09-30 2022-03-29 Tratamientos cognitivos medicinales

Country Status (11)

Country Link
US (1) US20230000843A1 (es)
EP (1) EP4037684A4 (es)
JP (1) JP2022550221A (es)
KR (1) KR20220080116A (es)
CN (1) CN114761005A (es)
AU (1) AU2020359291A1 (es)
CA (1) CA3152902A1 (es)
CL (1) CL2022000781A1 (es)
IL (1) IL292739A (es)
MX (1) MX2022003845A (es)
WO (1) WO2021062472A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202523658A (zh) * 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
CA3203010A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
CN120153257A (zh) * 2022-10-07 2025-06-13 射线质医疗有限公司 用于11β-HSD1抑制剂治疗的受试者选择
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5779181B2 (ja) * 2009-09-16 2015-09-16 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
EP2563780B1 (en) * 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1

Also Published As

Publication number Publication date
JP2022550221A (ja) 2022-11-30
KR20220080116A (ko) 2022-06-14
CN114761005A (zh) 2022-07-15
EP4037684A4 (en) 2023-11-01
WO2021062472A1 (en) 2021-04-08
MX2022003845A (es) 2022-06-22
EP4037684A1 (en) 2022-08-10
US20230000843A1 (en) 2023-01-05
AU2020359291A1 (en) 2022-04-21
CA3152902A1 (en) 2021-04-08
IL292739A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2022000143A (es) Metodos novedosos.
MX370361B (es) Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético.
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MX2019004484A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
DOP2023000060A (es) Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención
AR119159A1 (es) Tratamientos de angioedema
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
MX2025002228A (es) Metodos para el tratamiento o la profilaxis de la endometriosis
UY39593A (es) Tratamiento para tumores sólidos malignos
MX2022007854A (es) Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3.
BR112022005980A2 (pt) Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto
MX2024007937A (es) Tetrahidrobenzoazepinonas y analogos relacionados para la inhibicion de yap/taz-tead.
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
MX2023009482A (es) Tratamientos del sindrome de prader-willi.
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
CL2024003468A1 (es) Inhibidores de ripk1 y métodos de uso.
MX2025013157A (es) Tratamiento de afecciones inflamatorias que comprende imu-856
AR133890A1 (es) INHIBICIÓN DE LA INTEGRINA a₅b₁ HUMANA
AR114854A1 (es) Métodos para el tratamiento del cáncer